king pharmaceuticals  wikipedia king pharmaceuticals from wikipedia the free encyclopedia   redirected from alpharma jump to navigation search king pharmaceuticals type private foundation   industry pharmaceutical company health care headquarters bristol tennessee usa key people brian markison ceo joseph squicciarino cfo eric j bruce cto products pharmaceuticals revenue  billion usd  operating income  million usd  net income  million usd  number of employees  website wwwkingpharmcom king pharmaceuticals is a wholly owned subsidiary of pfizer based in bristol tennessee before being acquired by pfizer it was the worlds th largest pharmaceutical company on october   king was acquired by pfizer for  per share king produced a wide range of pharmaceuticals including altace for heart attack prevention levoxyl for hypothyroidism sonata a sleeping aid and skelaxin a muscle relaxant king pharmaceuticals operated manufacturing facilities in bristol tennessee rochester michigan st louis missouri st petersburg florida and middleton wisconsin they employed approximately  people including a sales force of over  individuals king pharmaceuticals inc was incorporated in the state of tennessee in  according to the king pharmaceutcals inc form k for the year ended december   filed with the us securities and exchange commission the wholly owned subsidiaries of king pharmaceuticals inc are monarch pharmaceuticals inc king pharmaceuticals research and development inc meridian medical technologies inc parkedale pharmaceuticals inc king pharmaceuticals canada inc and monarch pharmaceuticals ireland limited contents  company history  us marketing and distribution rights to altace™  acquisition  references  external links company historyedit king pharmaceuticals was founded in  john m gregory randal j kirk joseph joe r gregory jefferson jeff j gregory and james e gregoryin january  king acquired a former king college campus plant in bristol tennessee the squarefoot  m facility was purchased for  million from rsr pharmaceutical who had been using it after beecham merged with smithkline king initially manufactured drugs for other pharmaceutical companies but soon established a strategy of acquiring branded prescription drugs which have a much higher gross margin than contract manufactured drugs in february  king acquired  branded pharmaceuticals a sterile products manufacturing facility located in rochester michigan that it called the parkedale facility and some contract manufacturing contracts by december  king had placed its sterile products business into a subsidiary it named parkedale pharmaceuticals king pharmaceuticals obtained about twenty smaller branded drugs from the start up of the company until it went public in june  the king pharmaceuticals subsidiary monarch pharmaceuticals acquired one of its most profitable branded drugs altace later the same year on december   from hoechst marion roussel us marketing and distribution rights to altace™edit during  the us national right to life committee announced an antiru boycott targeting all hoechst pharmaceutical products including altace™ by september  the prolife organization pharmacists for life international joined the nrlc antiru boycott against the american subsidiary of hoechst ag hoechstroussel hoechstcelanese its generic subsidiary copley pharmaceuticals and the agricultural hoechst subsidiary while asking us consumers to focus on key hoechst drugs which have the most economic impact rather than taking an acrosstheboard shotgun approach and specifically targeting altace as a boycott list item hoechst merged with marion merrill dow of kansas city missouri in  forming the hoechst us pharmaceutical subsidiary hoechst marion roussel hmr altace was bringing in under  million in us revenues for hmr and hoechst had stopped promoting altace within the united states and king pharmaceuticals president jefferson jeff gregory also began negotiations in  with hoechst to acquire us distribution rights to altace the king pharmaceuticals wholly owned subsidiary monarch pharmaceuticals inc another brother of john gregory  joseph gregory  was then the president of monarch pharmaceuticals acquired ownership of the us distribution and marketing rights to altace and other hoescht products from hoescht ag subsidiary hoechst marion roussel of kansas city missouri on december   and following a january  merger a few weeks later with rhônepoulenc hoechst assumed the new corporate identity of aventis in  forbes magazine ranked john gregory among the  richest americans the bulk of gregorys personal fortune was due in large part due to the ability of king pharmaceuticals inc to reintroduce the hoechst branded prescription drug altace back into the us market under the king pharmaceuticalsinc subsidiary monarch pharmaceuticals brand following the  us marketing and distribution agreement between king pharmaceuticalsmonarch pharmaceuticals and ag hoechsthmr in late december  king pharmaceuticals dba monarch pharmaceuticals inc purchased the us marketing and distribution rights of the companys most successful drug altace for  million from the us subsidiary of hoechst ag hoechst marion roussel of kansas city as a result of increasing the number of sales representatives and the findings of the heart outcomes prevention evaluation hope altace sales skyrocketed using profits from altace king continued to add product lines the most significant purchases being levoxyl thrombin and cytomel in citation needed also in  seeing fewer opportunities to obtain branded drugs the company acquired an rd company based in north carolinacitation needed in  king and meridian medical technologies inc agreed that king would purchase merdian for  million in cash meridian was a manufacturer of autoinjectors including epipen an epinephrine autoinjector the deal was completed in january  in  john gregory stepped down as ceo and his brother jefferson gregory took over then in  jeff gregory stepped down as well after the sec began investigations into king’s medicaid billing practices the board named brian markison to replace him soon after in july  a deal was made for mylan laboratories to acquire king for  billion investors most notably carl icahn were critical of the merger saying that mylan was overpaying for king the next year the deal was called off in  king pharmaceuticals acquired alpharma pharmaceuticals to expand into the pain treatment market from the acquisition king gained the patents on the pain management drugs flector and embeda acquisitionedit on october   pfizer inc nyse pfe announced it would acquire bristolbased king pharmaceuticals inc for a total cost to pfizer of  billion in cash or  per share the acquisition was expected to expand pfizers product line of pain relief and management medication by adding king products such as embeda avinza and the flector patch other product lines that made king attractive to pfizer included the epipen for emergency delivery of medications and the alpharma animal health line referencesedit  a b c king pharmaceuticals  annual report  untitled document  httpwwwkingpharmcomfastfactsasp  pharmaceutical executive   top  pharmaceutical companies  pfizer to buy king pharmaceuticals for  billion the new york times october     king pharmaceuticals inc form k annual report for the fiscal year ended december   sec edgar   king pharmaceuticals inc  company history  httpswebarchiveorgwebhttpwwwkingpharmcomchairmanhtm king pharmaceuticals inc  message from our chairman  king pharmaceuticals amendment  to form s nasdaq june     press release king pharmaceuticals and hoechst marion roussel sign an agreement for one of the largest single product transactions in emerging pharmaceutical sector  evaluate king via evaluate december     a b c  pharmacists for life joins international boycott life communications november   abortion foes to boycott drugs altace made by ru manufacturer the virginiapilot associated press july    a b faith healers the bornagain gregory brothers worked a financial miracle from castoff drug brands forbes zina moukheiber october    monarch pharmaceuticals acquired sanofiaventis group december    httparchivetwstcomnotesarticlesjabhtml king pharmaceuticals ceo focuses on patented products  king pharmaceuticals oct   press release king pharmaceuticals to acquire meridian medical technologies  king pharmaceuticals form k filed for the fiscal year ended december    thestreetcom  king pharmaceuticals ceo to step down  robert steyer  kg  abboud leila berman dennis k july   mylan to buy king pharmaceuticals the wall street journal   king pharmaceuticals acquires alpharma they also gained a completely separate animal health division which focuses on the many agricultural and animal health needs of livestock animals  pfizer to acquire king pharmaceuticals inc  pfizer completes acquisition of king pharmaceuticals inc pfizer and king begin joint operations on march   press release pfizer march    external linksedit king pharmaceuticals fundinguniversecom  king pharmaceuticals inc  company history see altace and hoechst v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies retrieved from httpsenwikipediaorgwindexphptitlekingpharmaceuticalsoldid categories companies formerly listed on the new york stock exchangedefunct pharmaceutical companies of the united statescompanies based in tennesseepfizer brandslife sciences industryhidden categories pages using deprecated image syntaxall articles with unsourced statementsarticles with unsourced statements from october  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages deutsch edit links this page was last edited on  may  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view king pharmaceuticals  wikipedia king pharmaceuticals from wikipedia the free encyclopedia   redirected from alpharma jump to navigation search king pharmaceuticals type private foundation   industry pharmaceutical company health care headquarters bristol tennessee usa key people brian markison ceo joseph squicciarino cfo eric j bruce cto products pharmaceuticals revenue  billion usd  operating income  million usd  net income  million usd  number of employees  website wwwkingpharmcom king pharmaceuticals is a wholly owned subsidiary of pfizer based in bristol tennessee before being acquired by pfizer it was the worlds th largest pharmaceutical company on october   king was acquired by pfizer for  per share king produced a wide range of pharmaceuticals including altace for heart attack prevention levoxyl for hypothyroidism sonata a sleeping aid and skelaxin a muscle relaxant king pharmaceuticals operated manufacturing facilities in bristol tennessee rochester michigan st louis missouri st petersburg florida and middleton wisconsin they employed approximately  people including a sales force of over  individuals king pharmaceuticals inc was incorporated in the state of tennessee in  according to the king pharmaceutcals inc form k for the year ended december   filed with the us securities and exchange commission the wholly owned subsidiaries of king pharmaceuticals inc are monarch pharmaceuticals inc king pharmaceuticals research and development inc meridian medical technologies inc parkedale pharmaceuticals inc king pharmaceuticals canada inc and monarch pharmaceuticals ireland limited contents  company history  us marketing and distribution rights to altace™  acquisition  references  external links company historyedit king pharmaceuticals was founded in  john m gregory randal j kirk joseph joe r gregory jefferson jeff j gregory and james e gregoryin january  king acquired a former king college campus plant in bristol tennessee the squarefoot  m facility was purchased for  million from rsr pharmaceutical who had been using it after beecham merged with smithkline king initially manufactured drugs for other pharmaceutical companies but soon established a strategy of acquiring branded prescription drugs which have a much higher gross margin than contract manufactured drugs in february  king acquired  branded pharmaceuticals a sterile products manufacturing facility located in rochester michigan that it called the parkedale facility and some contract manufacturing contracts by december  king had placed its sterile products business into a subsidiary it named parkedale pharmaceuticals king pharmaceuticals obtained about twenty smaller branded drugs from the start up of the company until it went public in june  the king pharmaceuticals subsidiary monarch pharmaceuticals acquired one of its most profitable branded drugs altace later the same year on december   from hoechst marion roussel us marketing and distribution rights to altace™edit during  the us national right to life committee announced an antiru boycott targeting all hoechst pharmaceutical products including altace™ by september  the prolife organization pharmacists for life international joined the nrlc antiru boycott against the american subsidiary of hoechst ag hoechstroussel hoechstcelanese its generic subsidiary copley pharmaceuticals and the agricultural hoechst subsidiary while asking us consumers to focus on key hoechst drugs which have the most economic impact rather than taking an acrosstheboard shotgun approach and specifically targeting altace as a boycott list item hoechst merged with marion merrill dow of kansas city missouri in  forming the hoechst us pharmaceutical subsidiary hoechst marion roussel hmr altace was bringing in under  million in us revenues for hmr and hoechst had stopped promoting altace within the united states and king pharmaceuticals president jefferson jeff gregory also began negotiations in  with hoechst to acquire us distribution rights to altace the king pharmaceuticals wholly owned subsidiary monarch pharmaceuticals inc another brother of john gregory  joseph gregory  was then the president of monarch pharmaceuticals acquired ownership of the us distribution and marketing rights to altace and other hoescht products from hoescht ag subsidiary hoechst marion roussel of kansas city missouri on december   and following a january  merger a few weeks later with rhônepoulenc hoechst assumed the new corporate identity of aventis in  forbes magazine ranked john gregory among the  richest americans the bulk of gregorys personal fortune was due in large part due to the ability of king pharmaceuticals inc to reintroduce the hoechst branded prescription drug altace back into the us market under the king pharmaceuticalsinc subsidiary monarch pharmaceuticals brand following the  us marketing and distribution agreement between king pharmaceuticalsmonarch pharmaceuticals and ag hoechsthmr in late december  king pharmaceuticals dba monarch pharmaceuticals inc purchased the us marketing and distribution rights of the companys most successful drug altace for  million from the us subsidiary of hoechst ag hoechst marion roussel of kansas city as a result of increasing the number of sales representatives and the findings of the heart outcomes prevention evaluation hope altace sales skyrocketed using profits from altace king continued to add product lines the most significant purchases being levoxyl thrombin and cytomel in citation needed also in  seeing fewer opportunities to obtain branded drugs the company acquired an rd company based in north carolinacitation needed in  king and meridian medical technologies inc agreed that king would purchase merdian for  million in cash meridian was a manufacturer of autoinjectors including epipen an epinephrine autoinjector the deal was completed in january  in  john gregory stepped down as ceo and his brother jefferson gregory took over then in  jeff gregory stepped down as well after the sec began investigations into king’s medicaid billing practices the board named brian markison to replace him soon after in july  a deal was made for mylan laboratories to acquire king for  billion investors most notably carl icahn were critical of the merger saying that mylan was overpaying for king the next year the deal was called off in  king pharmaceuticals acquired alpharma pharmaceuticals to expand into the pain treatment market from the acquisition king gained the patents on the pain management drugs flector and embeda acquisitionedit on october   pfizer inc nyse pfe announced it would acquire bristolbased king pharmaceuticals inc for a total cost to pfizer of  billion in cash or  per share the acquisition was expected to expand pfizers product line of pain relief and management medication by adding king products such as embeda avinza and the flector patch other product lines that made king attractive to pfizer included the epipen for emergency delivery of medications and the alpharma animal health line referencesedit  a b c king pharmaceuticals  annual report  untitled document  httpwwwkingpharmcomfastfactsasp  pharmaceutical executive   top  pharmaceutical companies  pfizer to buy king pharmaceuticals for  billion the new york times october     king pharmaceuticals inc form k annual report for the fiscal year ended december   sec edgar   king pharmaceuticals inc  company history  httpswebarchiveorgwebhttpwwwkingpharmcomchairmanhtm king pharmaceuticals inc  message from our chairman  king pharmaceuticals amendment  to form s nasdaq june     press release king pharmaceuticals and hoechst marion roussel sign an agreement for one of the largest single product transactions in emerging pharmaceutical sector  evaluate king via evaluate december     a b c  pharmacists for life joins international boycott life communications november   abortion foes to boycott drugs altace made by ru manufacturer the virginiapilot associated press july    a b faith healers the bornagain gregory brothers worked a financial miracle from castoff drug brands forbes zina moukheiber october    monarch pharmaceuticals acquired sanofiaventis group december    httparchivetwstcomnotesarticlesjabhtml king pharmaceuticals ceo focuses on patented products  king pharmaceuticals oct   press release king pharmaceuticals to acquire meridian medical technologies  king pharmaceuticals form k filed for the fiscal year ended december    thestreetcom  king pharmaceuticals ceo to step down  robert steyer  kg  abboud leila berman dennis k july   mylan to buy king pharmaceuticals the wall street journal   king pharmaceuticals acquires alpharma they also gained a completely separate animal health division which focuses on the many agricultural and animal health needs of livestock animals  pfizer to acquire king pharmaceuticals inc  pfizer completes acquisition of king pharmaceuticals inc pfizer and king begin joint operations on march   press release pfizer march    external linksedit king pharmaceuticals fundinguniversecom  king pharmaceuticals inc  company history see altace and hoechst v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies retrieved from httpsenwikipediaorgwindexphptitlekingpharmaceuticalsoldid categories companies formerly listed on the new york stock exchangedefunct pharmaceutical companies of the united statescompanies based in tennesseepfizer brandslife sciences industryhidden categories pages using deprecated image syntaxall articles with unsourced statementsarticles with unsourced statements from october  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages deutsch edit links this page was last edited on  may  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view king pharmaceuticals  wikipedia king pharmaceuticals from wikipedia the free encyclopedia   redirected from alpharma jump to navigation search king pharmaceuticals type private foundation   industry pharmaceutical company health care headquarters bristol tennessee usa key people brian markison ceo joseph squicciarino cfo eric j bruce cto products pharmaceuticals revenue  billion usd  operating income  million usd  net income  million usd  number of employees  website wwwkingpharmcom king pharmaceuticals is a wholly owned subsidiary of pfizer based in bristol tennessee before being acquired by pfizer it was the worlds th largest pharmaceutical company on october   king was acquired by pfizer for  per share king produced a wide range of pharmaceuticals including altace for heart attack prevention levoxyl for hypothyroidism sonata a sleeping aid and skelaxin a muscle relaxant king pharmaceuticals operated manufacturing facilities in bristol tennessee rochester michigan st louis missouri st petersburg florida and middleton wisconsin they employed approximately  people including a sales force of over  individuals king pharmaceuticals inc was incorporated in the state of tennessee in  according to the king pharmaceutcals inc form k for the year ended december   filed with the us securities and exchange commission the wholly owned subsidiaries of king pharmaceuticals inc are monarch pharmaceuticals inc king pharmaceuticals research and development inc meridian medical technologies inc parkedale pharmaceuticals inc king pharmaceuticals canada inc and monarch pharmaceuticals ireland limited contents  company history  us marketing and distribution rights to altace™  acquisition  references  external links company historyedit king pharmaceuticals was founded in  john m gregory randal j kirk joseph joe r gregory jefferson jeff j gregory and james e gregoryin january  king acquired a former king college campus plant in bristol tennessee the squarefoot  m facility was purchased for  million from rsr pharmaceutical who had been using it after beecham merged with smithkline king initially manufactured drugs for other pharmaceutical companies but soon established a strategy of acquiring branded prescription drugs which have a much higher gross margin than contract manufactured drugs in february  king acquired  branded pharmaceuticals a sterile products manufacturing facility located in rochester michigan that it called the parkedale facility and some contract manufacturing contracts by december  king had placed its sterile products business into a subsidiary it named parkedale pharmaceuticals king pharmaceuticals obtained about twenty smaller branded drugs from the start up of the company until it went public in june  the king pharmaceuticals subsidiary monarch pharmaceuticals acquired one of its most profitable branded drugs altace later the same year on december   from hoechst marion roussel us marketing and distribution rights to altace™edit during  the us national right to life committee announced an antiru boycott targeting all hoechst pharmaceutical products including altace™ by september  the prolife organization pharmacists for life international joined the nrlc antiru boycott against the american subsidiary of hoechst ag hoechstroussel hoechstcelanese its generic subsidiary copley pharmaceuticals and the agricultural hoechst subsidiary while asking us consumers to focus on key hoechst drugs which have the most economic impact rather than taking an acrosstheboard shotgun approach and specifically targeting altace as a boycott list item hoechst merged with marion merrill dow of kansas city missouri in  forming the hoechst us pharmaceutical subsidiary hoechst marion roussel hmr altace was bringing in under  million in us revenues for hmr and hoechst had stopped promoting altace within the united states and king pharmaceuticals president jefferson jeff gregory also began negotiations in  with hoechst to acquire us distribution rights to altace the king pharmaceuticals wholly owned subsidiary monarch pharmaceuticals inc another brother of john gregory  joseph gregory  was then the president of monarch pharmaceuticals acquired ownership of the us distribution and marketing rights to altace and other hoescht products from hoescht ag subsidiary hoechst marion roussel of kansas city missouri on december   and following a january  merger a few weeks later with rhônepoulenc hoechst assumed the new corporate identity of aventis in  forbes magazine ranked john gregory among the  richest americans the bulk of gregorys personal fortune was due in large part due to the ability of king pharmaceuticals inc to reintroduce the hoechst branded prescription drug altace back into the us market under the king pharmaceuticalsinc subsidiary monarch pharmaceuticals brand following the  us marketing and distribution agreement between king pharmaceuticalsmonarch pharmaceuticals and ag hoechsthmr in late december  king pharmaceuticals dba monarch pharmaceuticals inc purchased the us marketing and distribution rights of the companys most successful drug altace for  million from the us subsidiary of hoechst ag hoechst marion roussel of kansas city as a result of increasing the number of sales representatives and the findings of the heart outcomes prevention evaluation hope altace sales skyrocketed using profits from altace king continued to add product lines the most significant purchases being levoxyl thrombin and cytomel in citation needed also in  seeing fewer opportunities to obtain branded drugs the company acquired an rd company based in north carolinacitation needed in  king and meridian medical technologies inc agreed that king would purchase merdian for  million in cash meridian was a manufacturer of autoinjectors including epipen an epinephrine autoinjector the deal was completed in january  in  john gregory stepped down as ceo and his brother jefferson gregory took over then in  jeff gregory stepped down as well after the sec began investigations into king’s medicaid billing practices the board named brian markison to replace him soon after in july  a deal was made for mylan laboratories to acquire king for  billion investors most notably carl icahn were critical of the merger saying that mylan was overpaying for king the next year the deal was called off in  king pharmaceuticals acquired alpharma pharmaceuticals to expand into the pain treatment market from the acquisition king gained the patents on the pain management drugs flector and embeda acquisitionedit on october   pfizer inc nyse pfe announced it would acquire bristolbased king pharmaceuticals inc for a total cost to pfizer of  billion in cash or  per share the acquisition was expected to expand pfizers product line of pain relief and management medication by adding king products such as embeda avinza and the flector patch other product lines that made king attractive to pfizer included the epipen for emergency delivery of medications and the alpharma animal health line referencesedit  a b c king pharmaceuticals  annual report  untitled document  httpwwwkingpharmcomfastfactsasp  pharmaceutical executive   top  pharmaceutical companies  pfizer to buy king pharmaceuticals for  billion the new york times october     king pharmaceuticals inc form k annual report for the fiscal year ended december   sec edgar   king pharmaceuticals inc  company history  httpswebarchiveorgwebhttpwwwkingpharmcomchairmanhtm king pharmaceuticals inc  message from our chairman  king pharmaceuticals amendment  to form s nasdaq june     press release king pharmaceuticals and hoechst marion roussel sign an agreement for one of the largest single product transactions in emerging pharmaceutical sector  evaluate king via evaluate december     a b c  pharmacists for life joins international boycott life communications november   abortion foes to boycott drugs altace made by ru manufacturer the virginiapilot associated press july    a b faith healers the bornagain gregory brothers worked a financial miracle from castoff drug brands forbes zina moukheiber october    monarch pharmaceuticals acquired sanofiaventis group december    httparchivetwstcomnotesarticlesjabhtml king pharmaceuticals ceo focuses on patented products  king pharmaceuticals oct   press release king pharmaceuticals to acquire meridian medical technologies  king pharmaceuticals form k filed for the fiscal year ended december    thestreetcom  king pharmaceuticals ceo to step down  robert steyer  kg  abboud leila berman dennis k july   mylan to buy king pharmaceuticals the wall street journal   king pharmaceuticals acquires alpharma they also gained a completely separate animal health division which focuses on the many agricultural and animal health needs of livestock animals  pfizer to acquire king pharmaceuticals inc  pfizer completes acquisition of king pharmaceuticals inc pfizer and king begin joint operations on march   press release pfizer march    external linksedit king pharmaceuticals fundinguniversecom  king pharmaceuticals inc  company history see altace and hoechst v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies retrieved from httpsenwikipediaorgwindexphptitlekingpharmaceuticalsoldid categories companies formerly listed on the new york stock exchangedefunct pharmaceutical companies of the united statescompanies based in tennesseepfizer brandslife sciences industryhidden categories pages using deprecated image syntaxall articles with unsourced statementsarticles with unsourced statements from october  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages deutsch edit links this page was last edited on  may  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view king pharmaceuticals  wikipedia king pharmaceuticals from wikipedia the free encyclopedia   redirected from alpharma jump to navigation search king pharmaceuticals type private foundation   industry pharmaceutical company health care headquarters bristol tennessee usa key people brian markison ceo joseph squicciarino cfo eric j bruce cto products pharmaceuticals revenue  billion usd  operating income  million usd  net income  million usd  number of employees  website wwwkingpharmcom king pharmaceuticals is a wholly owned subsidiary of pfizer based in bristol tennessee before being acquired by pfizer it was the worlds th largest pharmaceutical company on october   king was acquired by pfizer for  per share king produced a wide range of pharmaceuticals including altace for heart attack prevention levoxyl for hypothyroidism sonata a sleeping aid and skelaxin a muscle relaxant king pharmaceuticals operated manufacturing facilities in bristol tennessee rochester michigan st louis missouri st petersburg florida and middleton wisconsin they employed approximately  people including a sales force of over  individuals king pharmaceuticals inc was incorporated in the state of tennessee in  according to the king pharmaceutcals inc form k for the year ended december   filed with the us securities and exchange commission the wholly owned subsidiaries of king pharmaceuticals inc are monarch pharmaceuticals inc king pharmaceuticals research and development inc meridian medical technologies inc parkedale pharmaceuticals inc king pharmaceuticals canada inc and monarch pharmaceuticals ireland limited contents  company history  us marketing and distribution rights to altace™  acquisition  references  external links company historyedit king pharmaceuticals was founded in  john m gregory randal j kirk joseph joe r gregory jefferson jeff j gregory and james e gregoryin january  king acquired a former king college campus plant in bristol tennessee the squarefoot  m facility was purchased for  million from rsr pharmaceutical who had been using it after beecham merged with smithkline king initially manufactured drugs for other pharmaceutical companies but soon established a strategy of acquiring branded prescription drugs which have a much higher gross margin than contract manufactured drugs in february  king acquired  branded pharmaceuticals a sterile products manufacturing facility located in rochester michigan that it called the parkedale facility and some contract manufacturing contracts by december  king had placed its sterile products business into a subsidiary it named parkedale pharmaceuticals king pharmaceuticals obtained about twenty smaller branded drugs from the start up of the company until it went public in june  the king pharmaceuticals subsidiary monarch pharmaceuticals acquired one of its most profitable branded drugs altace later the same year on december   from hoechst marion roussel us marketing and distribution rights to altace™edit during  the us national right to life committee announced an antiru boycott targeting all hoechst pharmaceutical products including altace™ by september  the prolife organization pharmacists for life international joined the nrlc antiru boycott against the american subsidiary of hoechst ag hoechstroussel hoechstcelanese its generic subsidiary copley pharmaceuticals and the agricultural hoechst subsidiary while asking us consumers to focus on key hoechst drugs which have the most economic impact rather than taking an acrosstheboard shotgun approach and specifically targeting altace as a boycott list item hoechst merged with marion merrill dow of kansas city missouri in  forming the hoechst us pharmaceutical subsidiary hoechst marion roussel hmr altace was bringing in under  million in us revenues for hmr and hoechst had stopped promoting altace within the united states and king pharmaceuticals president jefferson jeff gregory also began negotiations in  with hoechst to acquire us distribution rights to altace the king pharmaceuticals wholly owned subsidiary monarch pharmaceuticals inc another brother of john gregory  joseph gregory  was then the president of monarch pharmaceuticals acquired ownership of the us distribution and marketing rights to altace and other hoescht products from hoescht ag subsidiary hoechst marion roussel of kansas city missouri on december   and following a january  merger a few weeks later with rhônepoulenc hoechst assumed the new corporate identity of aventis in  forbes magazine ranked john gregory among the  richest americans the bulk of gregorys personal fortune was due in large part due to the ability of king pharmaceuticals inc to reintroduce the hoechst branded prescription drug altace back into the us market under the king pharmaceuticalsinc subsidiary monarch pharmaceuticals brand following the  us marketing and distribution agreement between king pharmaceuticalsmonarch pharmaceuticals and ag hoechsthmr in late december  king pharmaceuticals dba monarch pharmaceuticals inc purchased the us marketing and distribution rights of the companys most successful drug altace for  million from the us subsidiary of hoechst ag hoechst marion roussel of kansas city as a result of increasing the number of sales representatives and the findings of the heart outcomes prevention evaluation hope altace sales skyrocketed using profits from altace king continued to add product lines the most significant purchases being levoxyl thrombin and cytomel in citation needed also in  seeing fewer opportunities to obtain branded drugs the company acquired an rd company based in north carolinacitation needed in  king and meridian medical technologies inc agreed that king would purchase merdian for  million in cash meridian was a manufacturer of autoinjectors including epipen an epinephrine autoinjector the deal was completed in january  in  john gregory stepped down as ceo and his brother jefferson gregory took over then in  jeff gregory stepped down as well after the sec began investigations into king’s medicaid billing practices the board named brian markison to replace him soon after in july  a deal was made for mylan laboratories to acquire king for  billion investors most notably carl icahn were critical of the merger saying that mylan was overpaying for king the next year the deal was called off in  king pharmaceuticals acquired alpharma pharmaceuticals to expand into the pain treatment market from the acquisition king gained the patents on the pain management drugs flector and embeda acquisitionedit on october   pfizer inc nyse pfe announced it would acquire bristolbased king pharmaceuticals inc for a total cost to pfizer of  billion in cash or  per share the acquisition was expected to expand pfizers product line of pain relief and management medication by adding king products such as embeda avinza and the flector patch other product lines that made king attractive to pfizer included the epipen for emergency delivery of medications and the alpharma animal health line referencesedit  a b c king pharmaceuticals  annual report  untitled document  httpwwwkingpharmcomfastfactsasp  pharmaceutical executive   top  pharmaceutical companies  pfizer to buy king pharmaceuticals for  billion the new york times october     king pharmaceuticals inc form k annual report for the fiscal year ended december   sec edgar   king pharmaceuticals inc  company history  httpswebarchiveorgwebhttpwwwkingpharmcomchairmanhtm king pharmaceuticals inc  message from our chairman  king pharmaceuticals amendment  to form s nasdaq june     press release king pharmaceuticals and hoechst marion roussel sign an agreement for one of the largest single product transactions in emerging pharmaceutical sector  evaluate king via evaluate december     a b c  pharmacists for life joins international boycott life communications november   abortion foes to boycott drugs altace made by ru manufacturer the virginiapilot associated press july    a b faith healers the bornagain gregory brothers worked a financial miracle from castoff drug brands forbes zina moukheiber october    monarch pharmaceuticals acquired sanofiaventis group december    httparchivetwstcomnotesarticlesjabhtml king pharmaceuticals ceo focuses on patented products  king pharmaceuticals oct   press release king pharmaceuticals to acquire meridian medical technologies  king pharmaceuticals form k filed for the fiscal year ended december    thestreetcom  king pharmaceuticals ceo to step down  robert steyer  kg  abboud leila berman dennis k july   mylan to buy king pharmaceuticals the wall street journal   king pharmaceuticals acquires alpharma they also gained a completely separate animal health division which focuses on the many agricultural and animal health needs of livestock animals  pfizer to acquire king pharmaceuticals inc  pfizer completes acquisition of king pharmaceuticals inc pfizer and king begin joint operations on march   press release pfizer march    external linksedit king pharmaceuticals fundinguniversecom  king pharmaceuticals inc  company history see altace and hoechst v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies retrieved from httpsenwikipediaorgwindexphptitlekingpharmaceuticalsoldid categories companies formerly listed on the new york stock exchangedefunct pharmaceutical companies of the united statescompanies based in tennesseepfizer brandslife sciences industryhidden categories pages using deprecated image syntaxall articles with unsourced statementsarticles with unsourced statements from october  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages deutsch edit links this page was last edited on  may  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view brian markison osmotica holdings corp ltd profile  biography  bloomberg feedback brian markison chief executive officer osmotica holdings corp ltd career history chief executive officer osmotica holdings corp ltd present avista capital partners lp  presidentceo fougera pharmaceuticals inc  presidentceo nycomed us inc  chairmanpresidentceo king pharmaceuticals inc  presidentceo king pharmaceuticals inc  acting presidentceo king pharmaceuticals inc  chief operating officer king pharmaceuticals inc  presidentoncology bristolmyers squibb co  presidentneuroscience bristolmyers squibb co  various positions bristolmyers squibb co  chairman avista capital partners lp unknown chairman vertical pharmaceuticals inc unknown senior vplicensing  external bristolmyers squibb co former vice presidentnortheast sales bristolmyers squibb co former sandoz ag former vpstrategy bristolmyers squibb co former presidentceo fougera pharmaceuticals inc former executive director vertical pharmaceuticals inc former chairman trigen holdings ag former show more website wwwosmoticacom corporate information address  sawyer road marietta ga  united states phone  fax  web url wwwosmoticacom from the web personal information education iona college bachelors degree  memberships board memberships lantheus mi intermediate inc chairman present komen foundation for south  central new jersey board member present avista healthcare public acquisition corp board member present lantheus holdings inc chairman present alere inc board member present lantheus mi holdings inc chairman present lantheus medical imaging inc chairman present rosetta genomics ltd chairman present alpharma inc board member present immunomedics inc lead director present pharmathene inc board member  lantheus mi holdings inc board member  lantheus holdings inc board member  lantheus medical imaging inc board member  fougera pharmaceuticals inc board member  nycomed us inc board member  rosetta genomics ltd board member  rosetta genomics ltd board member  king pharmaceuticals inc chairman  king pharmaceuticals inc board member  pharmacyclics inc board member  trigen holdings ag chairman former avista capital partners lp chairman unknown vertical pharmaceuticals inc chairman unknown show more other memberships komen foundation for south  central new jersey board member pennington schl trustee college of new jersey trustee show more sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data avista capital partners  team  brian markison  operating executive about avista approach investments team news investor login home team operating executives brian markison team partners investment professionals operating executives energy team operations brian markison operating executive mr markison was retained by avista capital partners in   mr markison is a seasoned executive with more than  years of operational marketing commercial development and sales experience with international pharmaceutical companies he most recently held the position of president and ceo and member of the board of directors of fougera pharmaceuticals inc a specialty pharmaceutical company in dermatology prior to its sale to sandoz the generics division of novartis ag  before leading fougera mr markison was chairman and ceo of king pharmaceuticals which he joined as coo in march  and was promoted to president and ceo later that year and elected chairman in  prior to joining king pharmaceuticals mr markison held various senior leadership positions at bristolmyers squibb including president of oncology virology and oncology therapeutics network president of neuroscience infectious disease and dermatology and senior vice president operational excellence and productivity mr markison holds a bs degree from iona college  he serves as chairman of the board of lantheus medical imaging rosetta genomics and osmotica pharmaceuticals and is on the board of directors of alere and immunomedics inc  he is also a director of the college of new jersey  operating executives håkan björklund charles harwood brian markison robert oneil dr patrick oneill phil seskin new york houston london   avista capital partners terms of use contact brian a markison  belrose welcome to belrose pharma official website contact   brian a markison   with over  years of experience in sales marketing strategic planning and general management mr markison is a healthcare industry executive at avista capital holdings currently serving as chairman of the avista portfolio company vertical  trigen holdings chairman of rosetta genomics nonexecutive chairman of the board at lantheus medical imaging and on the boards of directors at immunomedics inc alere and pharmathene previously he served as president and ceo of fougera pharmaceuticals until its sale to novartis and president ceo and chairman of king pharmaceuticals until its sale to pfizer before holding these positions mr markison served as acting president and ceo of zoetis products and at bristolmyers squibb company where he was president of the oncology virology and oncology therapeutics network and president of neuroscience  infectious disease and dermatology about us technology collaborations clinical partnering news search recent posts belrose pharma acquires enzon’s advanced drug formulation technology and clinical assets as foundation for driving development of more effective injectable and sustained release therapies belrose pharma launched to develop innovative therapeutics for diseases with high unmet medical needs news coverage inpharma belrose buys enzon’s pegylation platform and drug candidates pharma deals belrose pharma acquires enzon’s advanced drug formulation technology and associated clinical assets pharma mag belrose pharma acquires enzon’s advanced drug formulation technology and clinical assets pegylation archive enzon presents data from phase ii pegsn ezn study in patients with metastatic breast cancer enzon announces two oral presentations at the symposium of drug delivery systems in nanjing china enzon to present at  world congress and expo on biowaivers and biosimilars brian markison  king pharmaceuticals  inc  zoominfocom brian markison  linkedin linkedin main content starts below brian markisonsr director sales and marketing at unicarriers americas corporationlocationgreater chicago areaindustrywarehousingcurrentunicarriers americas corporationpreviousunicarriers americas corporation nissan forklift corp equipment depoteducationnorthern illinois university connectionsview brian’s full profile its freeyour colleagues classmates and  million other professionals are on linkedinview brian’s full profilebrian’s activitywe stand firm on forklift safety check out jamesradoussbrian likedel entrenamiento es clave para el buen servicio vegusabrian likedphotobrian likedive very proud to have assisted jennifer to achieve herbrian likedexperiencesr director sales and marketingunicarriers americas corporationseptember  – present  monthsdirector north america salesunicarriers americas corporationoctober  – september   yearssenior manager national accountsnissan forklift corpfebruary  – october   years  monthsnissan forklift corp and tcm merged to form unicarriers americas corporationmanagerequipment depot –   yearsmanagerwisconsin lift truck –   yearscontrollerfreund international –   yearsskillsmaterial handlingsalescustomer satisfactionmarketingcustomer servicepurchasingsales operationsmanagementwarehousingoperations managementteam buildingsales managementlogisticsnew business developmentinventory managementsee forecastingbudgetsaccount managementstrategic planningsupply chain managementincome statementcontract negotiationpricingmarketing strategysupply chainprocess improvementplnegotiationbbkey account managementsales processcrossfunctional team leadershippl managementbusiness developmentbusiness process improvementpricing strategybudgetingsee lesshows this translationgreat•has errorsthanks for your helpeducationnorthern illinois universitymaster accountingmaster accountinggroupsmhedachicago area logistics operations and supply chain professionalsmhimaterial handling professionalsview brian’s full profile tosee who you know in commonget introducedcontact brian directlyview brian’s full profileview this profile in another languageenglishgermanpeople also viewedcindy rodriguezmarketing specialistmike mayerpartner at advantage material handlingbrent hillabrandpresident at carolina handlingrandy minceygsa contract manager at toyota forklifts of atlantadennis m hearnecharlie vandenboschdirector north american sales at unicarriers americas formerly known as nissan forklift corporationjoe dejohnvicepresident sales manager  lift truck divisionsteve ciancivice president sales  marketing  sales growth  operations  marketing strategy  branding  product management  plgreg mcilveencorporate parts manager at trilift inceduardo torresdirector latin america sales unicarriers americas corporationpublic profile badgeinclude this linkedin profile on other websitesview profile badgessearch by nameover  million professionals are already on linkedin find who you knowfirst namelast nameexample jeff weinerlinkedin member directoryabcdefghijklmnopqrstuvwxyzmorebrowse members by country brian a markison  princeton nj  intelius sign in we found brian a markison in princeton nj brian a markison intelius found that brian a markison is a male between  and  years old from princeton nj we have connected them to  addresses  phones and  relatives or associates get report now age brian a markison is in his s brian has lived in princeton nj trenton nj bristol tn brians relatives joan markison elizabeth markison paul markison ben markison brian a markison zodiac signlibra gendermale professional status managing director at the kings academy get report now want to know more about brian get a comprehensive background report find full phone numbers and other contact information when available all from billions of available public records continue below for more details about brian or use our people search engine to find others get background check on brian a markison get a criminal check on brian a markison get a public record report on brian a markison get a people search report on brian a markison brian a markisons contact information known cities lived in find out where brian a markison has lived as well as brian a markisons phone numbers and email addresses brian a markison has lived in  states new jersey address for brian a markison  s r w princeton nj has lived in princeton nj trenton nj get full address report phone numbers associated with brian a markison    burlington vt    princeton nj    princeton nj get full phone report email addresses associated with brian a markison cacom bnnet bncom get email report brian a markisons professional information information regarding brian a markisons professional history find out previous places brian a markison has worked as well as dates employed the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act brian a markison has worked at  places company the kings academy title managing director company the kings academy title president brian a markisons experience title managing director company the kings academy job details king headquartered in bristol tennessee is a vertically integrated branded pharmaceutical company â king an sp  index company seeks to capitalize on opportunities in the pharmaceutical industry through the development including through inlicensing arrangements and acquisitions of novel branded prescription pharmaceutical products and technologies that complement the companys focus in specialtydriven markets particularly neuroscience and hospital â kings wholly owned subsidiary alpharma llc is also a leader in the development registration manufacture and marketing of pharmaceutical products for food producing animals title president company the kings academy job details company size  bil and above  employee range  to less than  additional professional information on brian a markison see brian a markisons linkedin profile brian a markisons social network and potential email matches find out potential social network profiles and potential email usernamed for brian a markison brian a markisons known social networks and potential email matches find all of brian a markisons social network profiles get full report search social networks including facebook linkedin myspace google twitter yahoo jigsaw zoominfo and more potential email matches brian markison username matches brianmarkison markisonbrian brianmarkison markisonbrian brianmarkison markisonbrian brianmarkison markisonbrian bmarkison popular email services gmailcom aolcom yahoocom comcastnet hotmailcom msncom rocketmailcom attnet sbcglobalnet ymailcom facebookcom mailcom bellsouthnet livecom earthlinknet coxnet prodigynet mecom peoplepccom junocom rediffmailcom mindspringcom comcastcom charternet outlookcom all trademarks product names company names or logos on this page are the property of their respective owners related people searches b markison intelius is a leading provider of public data about people and their connections to others intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fair credit reporting act fcra this site should not be used to determine an individual’s eligibility for credit insurance employment housing or any other purpose covered by the fcra for employment or tenant screening services please visit our partner talentwise about us site map about our reports blog help contact us   –  peopleconnect inc dba intelius all rights reserved privacy policy  updated terms of service  updated what is the fcra the fair credit reporting act fcra is a federal law that promotes the accuracy fairness and privacy of information in the files of consumer reporting agencies intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fcra intelius reports cannot be used for background checks related to consumer credit insurance employment housing or any other purpose prohibited under the fcra you may not use any information obtained from intelius for any purpose covered by the fcra find out more about the fcra here  markison profiles  linkedin linkedin main content starts below markison profilesshare on linkedinshare on facebookshare on twittershare on googlepublic profilelee markisonmanager  strategy corporate planning and analytics at verlocationgreater los angeles areaindustrymanagement consultingcurrentmanager  strategy corporate planning and analytics at ver senior manager  supply chain systems and operations at blue apronpastassistant vice president  lean transformation at bnp paribas project manager  research operations at moodys investors serviceeducationbucknell university bucknell universitysummaryi am excited by the constant challenges i face every day – both in and out of the office i spin my own wool design and create my ownview full profilepublic profilebrian markisonsr director sales and marketing at unicarriers americas corporationlocationgreater chicago areaindustrywarehousingcurrentsr director sales and marketing at unicarriers americas corporationpastdirector north america sales at unicarriers americas corporation senior manager national accounts at nissan forklift corp manager ateducationnorthern illinois universityview full profilepublic profilecoach markisone dispatchlocationgreater chicago areaindustrylaw enforcementcurrent dispatcher at marengo police and fire dispatchsoutheast emergency communicationseducationace certification  apco is nemec pro q a  hrs proqa emd training  hour telecommunicator training officer  supervisionsummaryleads agency coordinatormarengo police disptach supervisormarengo police dispatch scheduling coordinator for  full time and  parttimeview full profilepublic profileken markisonvice president and regulatory counsel at mortgage bankers associationlocationwashington dc metro areaindustryfinancial servicescurrentvice president and regulatory counsel at mortgage bankers association of americapastpresident at vocal moco associate vice president and regulatory counsel at mortgage bankers association assistant general counsel at useducationthe george washington university law school the george washington universitysummaryken markison is vice president and regulatory counsel at the mortgage bankers association in washington dc where he works on andview full profilepublic profilestacy markisonsenior director in vivo pharmacology  toxicologylocationgreater san diego areaindustrypharmaceuticalscurrentsenior director at crinetics pharmaceuticalspastdirector biology at senomyx inc associate director at senomyx inc principal scientist at neurocrine biosciences postdoctoral felloweducationuniversity of florida san diego state university san diego state universityview full profilepublic profilebenjamin markisonpharmaceutical supply chain analystlocationgreater new york city areaindustrypharmaceuticalscurrentsupply chain quality assurance analyst at osmotica pharmaceutical corp pharmaceutical sales representative at vertical pharmaceuticalspastsummer intern at vertical pharmaceuticals summer intern at comcastspectacor summer intern assisted the therapists at the rehabilitationeducationuniversity of miamiview full profilepublic profilegabrielle markisonbiomedical engineering student at rosehulman institute of technology locationgreater chicago areaindustrymechanical or industrial engineeringcurrentresisdent assistant at rosehulman institute of technology stockroom assistant at rosehulman institute of technologypastsophomore advisor at rosehulman institute of technologyeducationrosehulman institute of technology marengo community high schoolsummaryi am pursing a degree in biomedical engineering at rosehulman institute of technology i am a hard worker and thrive to learn somethingview full profilepublic profilejan markisonsenior safety representative at great west casualty companylocationgreater minneapolisst paul areaindustryinsurancecurrentsenior safety representative at great west casualty companypastvice president at daly agency inc senior loss control consultant at lockton companies safety director at bud meyer truck linescovenanteducationminnesota state university mankatoview full profilepublic profilerobert e markison mdhand surgeonlocationsan francisco bay areaindustrymedical practicecurrenthand surgeonpresidentownerclinical professor of surgery ucsf at a professional corporationpasthand surgeon at san francisco hand specialists hand surgeonassociate clinical professor of surgery at university of california saneducationdartmouth medical school columbia university in the city of new yorksummaryi enjoy caring for patients and i enjoy teaching premedical and medical students resident physicians colleagues hand therapistsview full profilepublic profilestephanie beckerdirector of community development at cypress hills local development corporationlocationgreater new york city areaindustrycivic  social organizationcurrentdirector of community development at cypress hills local development corporationpastprogram officer at enterprise community partnerseducationcolumbia university in the city of new york wesleyan universityview full profilejoin linkedin to see all  profilesjoin linkedinjoin linkedin to see all  profiles brian a markison of lantheus holdings inc board of directors   welcome company news company site premium log in membership home portfolio stocks bonds funds etfs cef markets tools real life finance discuss investing ideas fund analyst picks picks by category fund pick performance picks  pans enewsletter fund spy column fund spy book bond squad fund video reports fundinvestor newsletter etf investing fund family experts fund reports all fund analyst reports fund stewardship reports fund ratings highestrated value highestrated growth highestrated largecap highestrated midcap highestrated smallcap foreign fund standouts star rating performance rating methodology fund performance top month performers top ytd performers top year performers top year performers top year performers fund category returns biggest daily nav changes closedend funds exchangetraded funds quarterly market outlook fund screeners basic screeners fund screener longterm winners solid smallgrowth funds conservative bond funds premium screeners premium fund screener index funds hidden gems lowerrisk foreign funds video center lantheus holdings inc  lnth add to portfolioget email alertsprint this pagepdf reportdata questionquotechartstock analysisperformancekey ratiosfinancialsvaluationinsidersownershipfilingsbondsoverviewexecutive compensationinsider activitykey executivesboard of directorscommittees board of directors  brian a markison brian a markison non executive chairman of the board profile connections biography brian markison is the nonexecutive chairman of the board of directors mr markison joined the board of directors in september  and was elevated to chairman in january  mr markison has been a healthcare industry executive for avista since september  mr markison is a seasoned executive with more than  years of operational marketing commercial development and sales experience with international pharmaceutical companies he is currently the chief executive officer and a director of osmotica holdings scsp after serving as executive chairman of one of its predecessor companies verticaltrigen holdings llc previously he held the position of president and chief executive officer and member of the board of directors of fougera pharmaceuticals inc a specialty pharmaceutical company in dermatology prior to its sale to sandoz the generics division of novartis ag before leading fougera mr markison was chairman and chief executive officer of king pharmaceuticals which he joined as chief operating officer in march  and was promoted to president and chief executive officer later that year and elected chairman in  prior to joining king mr markison held various senior leadership positions at bristolmeyers squibb including president of oncology virology and oncology therapeutics network president of neuroscience infectious disease and dermatology and senior vice president operational excellence and productivity mr markison also serves on the board of directors of immunomedics inc on the board of directors of alere inc and as chairman of the board of directors for rosetta genomics ltd he is also a director of the college of new jersey mr markison holds a bachelor of science degree from iona college board membership company name board member since board committees immunomedics inc  boardcompensationfinancegovernance and nominatingnominatingresearch and development alere inc  auditboardcompensation rosetta genomics ltd  boardnominating and corporate governance brian a markison is connected to  board memberssee list of all board connections   we value your feedback let us know what you think site directory site map our products corrections help advertising opportunities licensing opportunities glossary rss mobile portfolio affiliate careers international sites australia canada china france germany hong kong italy the netherlands norway spain uk switzerland stocks by name  ticker  star rating  market cap  stock type  sector  industry mutual funds by star rating  investment style  total assets  category  top holdings  top sectors  symbol  ticker  name etfs by star rating  category  total assets  symbol  ticker  name articles by title  date  author  collection  interest  popularity investment categories by topic  sector  key indicators  user interest  market cap  industry premium stocks by name  ticker  star rating  market cap  stock type  sector  industry premium mutual funds by star rating  investment style  total assets  category  top holdings  top sectors  symbol  ticker  name premium etfs by star rating  category  total assets  symbol  ticker  name popular articles by title  date  author  collection  interest  popularity popular investment categories by topic  sector  key indicators  user interest  market cap  industry independent insightful trusted morningstar provides stock market analysis equity mutual fund and etf research ratings and picks portfolio tools and option hedge fund ira k and  plan research our reliable data and analysis can help both experienced enthusiasts and newcomers  copyright morningstar inc all rights reserved please read our terms of useand privacy policydow jones industrial average sp  nasdaq and morningstar index market barometer quotes are realtime russell  quote is  minutes delayed brian a markison executive profile  biography  bloomberg july    am et pharmaceuticals company overview of vertical  trigen holdings llc snapshotpeople  overviewboard memberscommittees executive profile brian a markison executive chairman vertical  trigen holdings llcagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationships background mr brian a markison has been an operating executive and healthcare industry executive of avista capital holdings lp since september   mrmarkison serves as the chief executive officer and chairman of osmotica holdings corp limited he has been executive chairman of vertical  trigen holdings llc at vertical pharmaceuticals llc since december   mr markison served as the chief executive officer and president of fougera pharmaceuticals inc from  july  to july  he joined king pharmaceuticals llc also known as king pharmaceuticals inc in march  and served as its president  chief executive officer from july  to march  and chairman from  to february  he served as the chief operating officer of king pharmaceuticals llc from joining on march   to july  and also served as its acting president since may  he served as the chief executive officer and president of alpharma llc since january  he held domestic general management positions within bristolmyers squibb company bms from  to  mr markison served as the president of oncology virology and oncology therapeutics network at bristolmyers squibb company where he served a number of key leadership roles throughout his career from  to  he served as a senior vice president of neuroscience and infectious disease president of neuroscience and infectious disease and dermatology and senior vice president of operational excellence and productivity at bristolmyers squibb company he served as vice president of northeast sales primary care mr markison served in various positions with bristolmyers squibb relating to marketing and sales he has been the chairman of rosetta genomics ltd since april   and has been its director since march  he has been the nonexecutive chairman of the board at lantheus medical imaging inc since january  and lantheus holdings inc since january   he has been director at avista healthcare public acquisition corp since october   he has been a director at lantheus medical imaging inc and lantheus holdings inc since september  he has been a director of immunomedics inc since october   and has been its lead independent director since october  he has been a director of alpharma llc since december  alere inc formerly inverness medical innovations inc since august  and nycomed us inc since august   he served as a director of lantheus mi intermediate inc since october   mr markison serves as a director of the college of new jersey and the pennington school inc he serves on the board of directors at komen foundation for southcentral new jersey he served as observer to the board of directors at rosetta genomics ltd since december  he served as director of king pharmaceuticals llc since july  he served as director at fougera pharmaceuticals inc from july  to july  he served as an independent director of pharmathene inc from september   to march   mr markison is a seasoned executive with more than  years of operational marketing commercial development and sales experience with international pharmaceutical companies mr markison received a bachelor of science from iona college in read full background corporate headquarters  main streetsayreville new jersey united statesphone fax  board members memberships directorthe college of new jerseydirectorthe pennington school incpresentlead independent directorimmunomedics incpresentdirectoralpharma llcpresentchairmanrosetta genomics ltdpresentnonexecutive chairmanlantheus holdings incpresentnonexecutive chairmanlantheus medical imaging incpresentdirectoralere incpresentexecutive chairmanvertical  trigen holdings llcpresentdirectoravista healthcare public acquisition corp education bs iona college other affiliations bristolmyers squibb companyalpharma llcimmunomedics incking pharmaceuticals llcalere incrosetta genomics ltdthe college of new jerseyiona collegefougera pharmaceuticals incthe pennington school incpharmathene inclantheus holdings incavista capital holdings lpvertical pharmaceuticals llclantheus mi intermediate inclantheus medical imaging incavista healthcare public acquisition corp annual compensation there is no annual compensation data available stocks options there is no stock options data available total compensation there is no total compensation data available request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact vertical  trigen holdings llc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close